Marie Delvenne, Valérie Bonhivers, Laurence Seidel, Philippe Delvenne, Bernard Duysinx, Guy Jerusalem, Renaud Louis
{"title":"[Retrospective study on smoking in lung cancer at the University Hospital of Liège].","authors":"Marie Delvenne, Valérie Bonhivers, Laurence Seidel, Philippe Delvenne, Bernard Duysinx, Guy Jerusalem, Renaud Louis","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>This retrospective study including 93 patients who presented a new diagnosis of lung cancer at the University Hospital of Liege between January 2023 and April 2023 analyzed the prevalence of smoking cessation following the diagnosis announcement. It was also investigated whether certain factors influenced this rate (stage, histology, type of treatment received, tobacco monitoring,…) and whether the impact of this smoking cessation influenced the progression of the disease and the response to oncological treatments. The results show that 34.8 % of active smokers at diagnosis experienced smoking cessation at 6 months and 32.6 % at 1 year. This success rate of more than 30 % at 1 year is considerably higher than the success rates observed in individuals who attempt to obtain smoking cessation spontaneously and independently, outside of a cancer diagnosis (3-5 %). However, it remains low if one consider that smoking cessation is an important factor for increasing the survival rate for this type of cancer. It should be noted that, among the 51 smokers still active, 42 (82.4 %) did not consult a tobacco specialist. Smoking cessation support should in fact be offered to patients diagnosed with lung cancer more systematically and as early as possible in order to optimize the effectiveness of treatments and to increase the chances of survival.</p>","PeriodicalId":94201,"journal":{"name":"Revue medicale de Liege","volume":"79 11","pages":"701-710"},"PeriodicalIF":0.0000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revue medicale de Liege","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
This retrospective study including 93 patients who presented a new diagnosis of lung cancer at the University Hospital of Liege between January 2023 and April 2023 analyzed the prevalence of smoking cessation following the diagnosis announcement. It was also investigated whether certain factors influenced this rate (stage, histology, type of treatment received, tobacco monitoring,…) and whether the impact of this smoking cessation influenced the progression of the disease and the response to oncological treatments. The results show that 34.8 % of active smokers at diagnosis experienced smoking cessation at 6 months and 32.6 % at 1 year. This success rate of more than 30 % at 1 year is considerably higher than the success rates observed in individuals who attempt to obtain smoking cessation spontaneously and independently, outside of a cancer diagnosis (3-5 %). However, it remains low if one consider that smoking cessation is an important factor for increasing the survival rate for this type of cancer. It should be noted that, among the 51 smokers still active, 42 (82.4 %) did not consult a tobacco specialist. Smoking cessation support should in fact be offered to patients diagnosed with lung cancer more systematically and as early as possible in order to optimize the effectiveness of treatments and to increase the chances of survival.